Drug intelligence / Profile preview

GLA-015

Development stage: Unknown
Lead developer: Glatt Pharmaceutical Services
Modality: Small Molecules
Administration: Oral

Overview

GLA-015 is a novel cannabidiol (CBD) granules formulation developed by Glatt Pharmaceutical Services GmbH & Co. KG. It is intended for the treatment of Coronavirus disease 2019 (COVID-19). This new formulation is designed to offer enhanced solubility, increased bioavailability, reduced variability, especially in the fasted state, and improved robustness towards food interaction compared to existing oil-based cannabidiol solutions.

Brand names: Nantheia A1002
Other names: Cannabidiol 1500 mg 29,7% w/w GRA BLD P

Targets

CNR1 (Cannabinoid receptor 1)PPARG (Peroxisome proliferator-activated receptor gamma)TRPV1 (Transient receptor potential cation channel subfamily V member 1)UGT (UDP-glucuronosyltransferase family)Cyp (Cyclophilin family)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))GPR55 (G protein-coupled receptor 55)FAAHGABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on GLA-015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLA-015.

Explore the full profile